News

Get the latest newsflashes from reMYND.

reMYND announces positive Phase 2a clinical trial results for treatment of mild-to-moderate Alzheimer’s disease
30-10-2024

Leuven, Belgium, Wed 30 October 2024: reMYND, a biotech company developing treatments for neurodegenerative disorders like Alzheimer’s and Huntington's disease, announces promising results from its Phase 2a clinical trial investigating septin modulation in patients with mild-to-moderate Alzheimer’s disease. The trial participants demonstrated significant improvement on memory tests, marking an important milestone in the pursuit of effective Alzheimer’s disease treatments.

Read more
reMYND appoints new CEO and Chairman to progress novel Alzheimer’s Disease program through clinical development
03-09-2024

Leuven Belgium, 03 September 2024: reMYND NV, a biotech company active in the field of neurodegeneration, is pleased to announce changes to its management team and Board of Directors, with the appointment of Floor Stam as CEO and Johan Cardoen as Chairman.

Read more
reMYND announces publication in Science of novel drug target with potential for development into transformative treatments for Alzheimer’s disease
30-05-2024

reMYND’s septin modulator program demonstrated neuroprotective qualities in Alzheimer’s disease models

Findings provide support for deregulated calcium signalling as a key-driver of neurodegeneration

Read more
reMYND announces publication in Alzheimer’s and Dementia on pivotal role of cytosolic calcium in Alzheimer’s disease
03-05-2023

Leuven Belgium, 3 May 2023: reMYND NV, a clinical stage company addressing neurodegeneration, is pleased to announce the publication of a review article in this month’s edition of Alzheimer’s and Dementia, exploring the role of calcium dyshomeostasis in driving neurodegeneration in dementia, particularly Alzheimer’s disease (AD).

Read more
reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration
29-08-2022

Leuven Belgium, 31 August 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces positive preclinical results from its drug discovery program ReS18-H to treat Huntington’s Disease (HD), a rare monogenic disease that causes the progressive breakdown of nerve cells in the brain by neurotoxic mutant huntingtin, leading to movement, cognitive and psychiatric dysfunction.

Read more
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
03-05-2022

Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has successfully completed its Phase 1 study. Topline data has demonstrated excellent brain exposure and strong safety profile. These results support the next phase of clinical development, a Phase 2a proof-of-mechanism study slated for initiation soon.

Read more
reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program
04-11-2021

Leuven Belgium, 4 November 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction, today announces the acceptance of ReS3-T, the Company’s lead epilepsy drug candidate, into the US NIH’s National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3).

Read more
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
21-10-2021

Leuven Belgium, 21 October 2021: reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.

Read more
reMYND announces Clinical Advisory Board to support development of Alzheimer’s programme
19-05-2021

Leuven Belgium, 20 May 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction, is pleased to announce the Clinical Advisory Board (CAB) which will support the Company as it progresses its programme in Alzheimer’s disease (“Alzheimer’s”).

Read more
reMYND appoints Dr. Lode Debrabandere as Chief Business Officer
17-03-2021
Read more
reMYND extends Series B funding to EUR 24 million
20-01-2021

- Financing enables advancement of key programs in Alzheimer's and Diabetes through Clinical Proof of Concept in 2022

- Additional EUR 12 million raised

Read more
reMYND commences first-in-human trial of ReS19-T Alzheimer’s program
02-12-2020

-  RES-19T represents a novel approach to treat Alzheimer’s at the root of the disease and restore cognition

-  Board and Senior Leadership team strengthened; appointment of Staph Leavenworth Bakali as Chair and Hermann Russ as Chief Medical Officer

 

Read more
Interreg. project "Memories" update
01-07-2020

An intermediate update on the progress of identifying differently expressed microRNA in Alzheimer's Disease.

Read more
Interreg. project "Memories" holds 2nd annual symposium & new newsletter is available
03-09-2019

The Interreg. Flanders-Netherlands project "Memories" (Dutch: "Herinneringen") will hold its 2nd annual Symposium on December 16th, 2019 in Leuven. The initial gathered data on activated mechanisms after addition of Alzheimer-related mechanisms will be presented. The intermediary update is available in the third newslette. Visit https://herinneringen.eu/en/documents to receive the latest updates.

Read more
reMYND raises 12 million EUR to assess clinical proof-of-mechanism in Alzheimer’s and to expand into orphan disorders
17-12-2018

Leuven Belgium, December 18th, 2018: reMYND NV announced today the closing of a 12 million EUR financing round to

  • advance its Alzheimer program into clinical testing and assess its novel mechanism in patients;
  • broaden the pipeline into CNS orphan programs, including Huntington and ALS;
  • further innovate and expand the service offering of its CRO;
  • and strengthen the executive team and board.
Read more
Approved project ‘Memories’: early diagnostics of Alzheimer’s disease (AD)
08-03-2018

Interreg granted a positive ruling on the project ‘Memories’ mid-December. reMYND will team up with the consortium partners ToxGenSolutions, Icometrix, KU Leuven, Maastricht University and UAntwerpen to support AD research aimed at a sustainable, inclusive growth among Flanders and South-Netherlands. The entire project will receive almost € 800.000 in funding from Interreg. The province of Flemish Brabant will support the project with an additional sum of nearly € 150.000.

Read more
reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive neuronal loss correlating with development of Tau pathology
29-03-2017
Neuronal loss, a pathological hallmark of Alzheimer’s disease, is recapitulated in reMYND’s transgenic human hTauP301L mouse model.
Read more
reMYND’s transgenic hTauP301L model of Alzheimer’s disease displays progressive astrocytosis and microgliosis correlating with development of Tau pathology
14-03-2017
The role of microglia and astrocytes in Alzheimer’s disease and how these contribute to neuronal loss has gained increased interest over the past years.
Read more
reMYND receives grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s
14-03-2017
reMYND NV today announced that it has received two grants from Flanders and Europe to advance break-through treatments in Epilepsy and Alzheimer’s respectively.
Read more
A novel transgenic mouse model showing the exacerbating interplay between Abeta- and Tau.P301S-driven pathology
10-06-2016

The interplay of Ab and Tau is still considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease. You can now also assess the effects of your experimental Alzheimer’s Disease treatment on both amyloid- and tau pathology in the cross of our APP-london and Tau.P301S transgenic mouse models, in which APP-london aggravates the Tau-effect.

Read more
reMYND signs the Statement in support of animal research and a transparent approach
22-04-2016
reMYND, has joined with 21 other organisations from across the life sciences sector in signing up to a declaration on openness on animal research.
Read more
reMYND to present on Biotechdag
19-10-2015
reMYND will be presenting on the research towards the treatment of Alheimers and diabetes worldwide.
Read more
Measuring cognition in reMYND’s Tau animal models
24-06-2015
reMYND’s Tau.P301L and Tau.P301S models feature progressive hyperphosphorylation of Tau with age.
Read more
IWT supports reMYND in developing a cure for Type 1 Diabetes
23-06-2015
reMYND announced that it has received a grant from IWT to assess the potential of its Diabetes program in curing Type 1 Diabetes Mellitus (T1DM).
Read more
Longitudinal imaging of Tau aggregates in vivo by two-photon imaging available in reMYND’s Tau.P301S model
06-03-2015
Two-photon imaging allows tracking the formation of Tau aggregates in the same brain-region of a live animal over the course of time.
Read more
Transgenic mouse model of combined Abeta and tau pathology
17-12-2014
The interplay of Abeta and Tau is considered detrimental if not crucial for disease etiology and progression of Alzheimer’s Disease.
Read more
Robust LTP measurements in Tau models
12-11-2014
LTP is gaining importance as a functional ex-vivo or even in-vivo read-out related to learning and memory.
Read more
LTP measurements available through reMYND
11-08-2014
reMYND now offers LTP measurements to allow clients to assess the effect of their experimental Alzheimer treatment.
Read more
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
05-05-2014
reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice
Read more
Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
27-03-2014
Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement.
Read more
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment
27-03-2014
Roche presents preclinical efficacy data gathered in collaboration with reMYND’s CRO on a promising combo Alzheimer treatment.
Read more
Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
27-03-2014
Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.
Read more
Tulips for Parkinson’s
18-03-2014
For 2014, reMYND has dedicated the proceeds of its new year cards to the Vlaamse Parkinson Liga as part of StuBru’s Music-for-Life action.
Read more
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
04-11-2013
In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.
Read more
BMS publishes paper in collaboration with reMYND showing dose-dependent effects of donepezil on brain Abeta and cognition in MWM
08-07-2013

“Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease”.

Read more
reMYND launches a project aimed at improving the predictability of preclinical Alzheimer models as part of the prestigious Marie-Curie International Training Network NPlast
06-09-2012
reMYND NV announced today its project in NPlast, a prestigious International Training Network funded by the European Commission that is to be launched April 27-28th 2012 at the Leibniz-Institut für Neurobiologie in Magdeburg, Germany.
Read more
Ajit Shetty strengthens reMYND’s Board of Directors
21-08-2012
reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.
Read more
reMYND’s grant from the Michael J Fox Foundation in SciBX
17-08-2011
The Science-Business eXchange devoted an article to the role the Michael J Fox Foundation has been playing in PD therapeutics.
Read more
IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
27-06-2011
reMYND NV today announced that it has received a grant of 1.48 million EUR to accelerate its Diabetes program.
Read more
reMYND’s CRO receives governmental grant for a continued innovation of its offering
09-05-2011
The governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization.
Read more
reMYND's CRO announces quarterly digital Newsletter
08-02-2011
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease.
Read more
Review in Nature highlights reMYND's discovery platform
15-11-2010
The growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases was featured in Nature Reviews Drug Discovery.
Read more
reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
08-09-2010

New data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing.

Read more
reMYND and Amorfix announce agreement
06-07-2010
Amorfix Life Sciences Ltd. (TSX:AMF) and reMYND nv today announced the signing of a partnership agreement.
Read more
Ablynx and reMYND settle dispute amicably
02-06-2010
Ablynx nv [Euronext Brussels: ABLX] and reMYND nv announced today that they have reached a settlement.
Read more
reMYND receives a grant of 0.9 million EUR from IWT
10-12-2009
reMYND receives a grant of 0.9 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND receives license renewal from Schering-Plough for RadarScreen
18-11-2009
reMYND nv announced today that it has received the renewal of the non-exclusive license agreement with Schering-Plough.
Read more
reMYND receives award for Company with an exceptional relevance to society
21-09-2009
reMYND received 'the 1st Award for Company with an exceptional relevance to society'.
Read more
reMYND awarded by the Michael J. Fox Foundation
21-07-2009
reMYND is one of the nine biotech and pharmaceutical companies that have been awarded by the Michael J. Fox Foundation
Read more
reMYND receives a grant of almost 1 million EUR from IWT
10-12-2008
reMYND receives a grant of almost 1 million EUR from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).
Read more
reMYND's Lead Alzheimer drug demonstrates neuroprotection
15-11-2008
reMYND's Lead Alzheimer drug demonstrates neuroprotection in 2 transgenic animal models of TAU and Amyloid bèta pathology.
Read more
reMYND licenses highly innovative transgenic mouse models
20-08-2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven.
Read more
reMYND installs world-class scientific advisory board
25-06-2008
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.
Read more
Lead product for treating Parkinson's Disease demonstrates efficacy
15-03-2008
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease.
Read more
reMYND's Parkinson's disease drug discovery program reaches breakthrough
26-03-2007
reMYND nv has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.
Read more